bioRxiv Science⌕ Search

Biology subjects

Fani, S.

Publications and source records attributed to Fani, S..

2 recordsLinked to original sources

COATS Identifies Copy-Number-Dependent Drivers and Enablers of Aneuploidy in Cancer

Aneuploidy is a hallmark of most cancers but at the same time has been shown to decrease cellular fitness. Thus, to solve this conundrum, a current hypothesis in the field is that specific SCNAs may promote tolerance to the aneuploid state and/or promote additional chromosomal instability (CIN) and more aneuploidy. In other words, gains or losses of oncogenes (OGs) and tumor suppressor genes (TSGs) can, in turn, drive further CIN, promoting additional somatic alterations, or enhance aneuploid cell survival. Despite their importance, CN-dependent OGs and TSGs associated with aneuploidy remain largely unidentified. Here, we present a new method, Copy-number-dependent Oncogenes And Tumor Suppressors (COATS), to identify pan-cancer and cancer-specific CN-dependent OGs and TSGs associated with aneuploidy (Aneu-OGs and Aneu-TSGs). COATS integrates information theory and statistical tests to analyze gene expression, copy number, and aneuploidy, and incorporates timing analysis to distinguish early drivers of CIN from late tolerance enablers. Interestingly, using the CINner simulation framework, we show that aneuploidy drivers tend to occur earlier than aneuploidy enablers. Applying COATS to 33 TCGA cancer types, we identified 479 pan-cancer amplification-dependent Aneu-OGs and 141 deletion-dependent Aneu-TSGs. For validation, we used shRNA to knock down CCT5, a COATS-identified pan-cancer Aneu-OG predicted to promote aneuploidy tolerance, in isogenic aneuploid and near-diploid cells. Strikingly, CCT5 depletion was selectively toxic in aneuploid cells, supporting its classification as an aneuploidy tolerance enabler gene. Overall, our study defines a set of CN-dependent genes associated with aneuploidy and points to candidate therapeutic targets for chromosomally unstable cancers.

Cancer Biology↗

KaryoCreate: a new CRISPR-based technology to generate chromosome-specific aneuploidy by targeting human centromeres

Aneuploidy, the presence of chromosome gains or losses, is a hallmark of cancer and congenital syndromes. Here, we describe KaryoCreate (Karyotype CRISPR Engineered Aneuploidy Technology), a system that enables generation of chromosome-specific aneuploidies by co-expression of a sgRNA targeting chromosome-specific CENPA-binding [a]-satellite repeats together with dCas9 fused to a mutant form of KNL1. We designed unique and highly specific sgRNAs for 19 out of 24 chromosomes. Expression of these sgRNAs with KNL1Mut-dCas9 leads to missegregation and induction of gains or losses of the targeted chromosome in cellular progeny with an average efficiency of 8% and 12% for gains and losses, respectively (up to 20%), tested and validated across 9 chromosomes. Using KaryoCreate in colon epithelial cells, we show that chromosome 18q loss, a frequent occurrence in gastrointestinal cancers, promotes resistance to TGF{beta}, likely due to synergistic hemizygous deletion of multiple genes. Altogether, we describe a novel technology to create and study chromosome missegregation and aneuploidy in the context of cancer and beyond. HighlightsO_LIWe designed sgRNAs targeting chromosome-specific centromeres across 19 human chromosomes C_LIO_LIKaryoCreate combines chromosome-specific centromeric sgRNAs with dCas9 fused to a mutant form of KNL1. C_LIO_LIKaryoCreate allows engineering gains and losses of specific human chromosomes. C_LIO_LIEngineered Chromosome 18q loss promotes tumor-associated phenotypes in colon-derived cells. C_LIO_LIKaryoCreate is a CRISPR-based technology to foster the study of centromere biology and aneuploidy. C_LI

cell biology↗